You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameErythromycin
Accession NumberDB00199  (APRD00953)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

Erythromycin is a macrolide antibiotic produced by Streptomyces erythreus. It inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits; binding inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.

Structure
Thumb
Synonyms
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
3''-O-demethylerythromycin
Abomacetin
Eritromicina
Erythromycin
Erythromycin A
Erythromycin C
Erythromycine
Erythromycinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-erythromycin Tab 250mg USPtablet (enteric-coated)250 mgoralAltimed Pharma Inc.1985-12-311999-09-17Canada
Diomycin-ont 5mg/gmointment5 mgophthalmicDioptic Pharmaceuticals Inc1997-09-11Not applicableCanada
E.E.sgranule, for suspension200 mg/5mLoralA S Medication Solutions Llc2011-04-18Not applicableUs
E.E.sgranule, for suspension200 mg/5mLoralArbor Pharmaceuticals, Inc.2011-04-18Not applicableUs
E.E.sgranule, for suspension200 mg/5mLoralArbor Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ees 600 Tablets 600mgtablet600 mgoralAmdipharm Limited1983-12-31Not applicableCanada
Ees-200powder for suspension40 mgoralAmdipharm Limited1962-12-31Not applicableCanada
Ees-200 Chewable Tbs (eryped)tablet200 mgoralAbbott Laboratories, Limited1964-12-311997-08-18Canada
Ees-400powder for suspension400 mgoralAmdipharm Limited1978-12-31Not applicableCanada
Emycin Ect 250mgtablet (enteric-coated)250 mgoralThe Upjohn Company Of Canada1969-12-311996-09-10Canada
Ery-pedsuspension200 mg/5mLoralArbor Pharmaceuticals, Inc.2011-07-05Not applicableUs
Ery-pedsuspension400 mg/5mLoralArbor Pharmaceuticals, Inc.2012-06-14Not applicableUs
Erybidtablet500 mgoralAmdipharm Limited1990-12-31Not applicableCanada
Eryc Delayed-release Capsulescapsule (enteric-coated)333 mgoralPfizer Canada Inc1990-12-31Not applicableCanada
Eryc Delayed-release Capsulescapsule (enteric-coated)250 mgoralPfizer Canada Inc1983-12-31Not applicableCanada
Erygelgel20 mg/gtopicalPrestium Pharma, Inc.2016-01-27Not applicableUs
Erymycin Ophthalmic Ointment 5mg/gointment5 mgophthalmicMm Therapeutics Inc1998-06-042011-01-05Canada
Erythro-500 Tab 500mg USPtablet500 mgoralPro Doc Limitee1987-12-312009-07-23Canada
Erythro-basetablet250 mgoralAa Pharma Inc1986-12-31Not applicableCanada
Erythro-base Tab 250mg USPtablet250 mgoralPro Doc Limitee1987-12-312009-07-23Canada
Erythro-ECcapsule (enteric-coated)333 mgoralAa Pharma Inc1991-12-312014-11-07Canada
Erythro-ECcapsule (enteric-coated)250 mgoralAa Pharma Inc1989-12-312014-11-07Canada
Erythro-EStablet600 mgoralAa Pharma Inc1986-12-31Not applicableCanada
Erythro-ES Tab 600mg USPtablet600 mgoralPro Doc Limitee1987-12-312009-07-23Canada
Erythro-Stablet250 mgoralAa Pharma Inc1981-12-31Not applicableCanada
Erythro-Stablet500 mgoralAa Pharma Inc1986-12-31Not applicableCanada
Erythrocin Filmtab 250mgtablet250 mgoralAbbott Laboratories, Limited1955-12-311999-08-09Canada
Erythrocin Filmtab 500mgtablet500 mgoralAbbott Laboratories, Limited1973-12-311999-08-09Canada
Erythrocin I.V.powder for solution500 mgintravenousAmdipharm Limited1988-12-31Not applicableCanada
Erythrocin I.V.powder for solution1 gintravenousAmdipharm Limited1988-12-31Not applicableCanada
Erythrocin IVpowder for solution500 mgintravenousAbbott Laboratories, Limited1966-12-311996-11-04Canada
Erythrocin IVpowder for solution1 gintravenousAbbott Laboratories, Limited1954-12-311996-11-04Canada
Erythrocin Lactobionateinjection, powder, lyophilized, for solution500 mg/10mLintravenousHospira, Inc.1986-09-24Not applicableUs
Erythrocin Liq 250liquid50 mgoralAbbott Laboratories, Limited1973-12-312006-06-12Canada
Erythrocin Liquid 125liquid25 mgoralAbbott Laboratories, Limited1970-12-312006-06-12Canada
Erythromid Tab 250mgtablet250 mgoralAbbott Laboratories, Limited1972-12-312008-06-06Canada
Erythromycingel20 mg/gtopicalRenaissance Pharma, Inc.2015-07-01Not applicableUs
Erythromycincapsule, delayed release pellets250 mg/1oralMidlothian Laboratories2013-07-29Not applicableUs
Erythromycin Capsules USP 250mgcapsule250 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Erythromycin Ophthalmic Ointment U.S.P.ointment5 mgophthalmicRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Erythromycin Stearate Tablets USP 250mgtablet250 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Erythromycine 250 Tabtablet250 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Ilosone 250mg Pulvule 375capsule250 mgoralEli Lilly Canada Inc1956-12-312000-08-03Canada
Ilosone Liquid 125mg/5mlsuspension125 mgoralEli Lilly Canada Inc1968-12-311999-08-11Canada
Ilosone Liquid 250mg/5mlsuspension250 mgoralEli Lilly Canada Inc1972-12-312000-08-03Canada
Ilotycin Cryst Op Ont 0.5% 52ointment.5 %ophthalmicEli Lilly Canada Inc1954-12-312002-07-26Canada
Ilotycin Gluceptate IV Ampoule 646 1gmpowder for solution1 gintravenousEli Lilly Canada Inc1957-12-311999-09-13Canada
Novo-rythro Encap 250mgcapsule (enteric-coated)250 mgoralNovopharm Limited1990-12-312005-08-10Canada
Novo-rythro Estolate Cap 250mgcapsule250 mgoralNovopharm Limited1970-12-312005-08-10Canada
Novo-rythro Estolate Suspensionsuspension125 mgoralTeva Canada Limited1970-12-31Not applicableCanada
Novo-rythro Estolate Suspensionsuspension250 mgoralTeva Canada Limited1973-12-31Not applicableCanada
Novo-rythro Ethylsuccinate Pwr 400mg/5mlpowder400 mgoralNovopharm Limited1985-12-312015-10-26Canada
Novo-rythro Ethylsuccinate Pwspowder for solution100 mgoralNovopharm Limited1984-12-312005-08-10Canada
Novo-rythro Ethylsuccinate Pwspowder for solution200 mgoralNovopharm Limited1984-12-312015-10-26Canada
Novo-rythro Stearate Tab 250mgtablet250 mgoralNovopharm Limited1977-12-312005-08-10Canada
Nu-erythromycin-S 250mg Tabletstablet250 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Odan-erythromycinointment5 mgophthalmicOdan Laboratories Ltd1992-12-31Not applicableCanada
Onguent Ophtalmique D'erythromycine USPointment5 mgophthalmicLaboratoires Sterigen Inc2010-02-12Not applicableCanada
Pcetablet333 mgoralAmdipharm Limited1988-12-31Not applicableCanada
Pcetablet500 mg/1oralArbor Pharmaceuticals, Inc.2011-10-05Not applicableUs
Pcetablet333 mg/1oralArbor Pharmaceuticals, Inc.2011-10-05Not applicableUs
Pdp-erythromycinointment5 mgophthalmicPendopharm Division Of De Pharmascience Inc1991-12-31Not applicableCanada
Sterile Erythromycin Lactobionate Pws 1000mgpowder for solution1 gintravenousNovopharm Limited1992-12-312015-10-26Canada
Sterile Erythromycin Lactobionate Pws 500mgpowder for solution500 mgintravenousNovopharm Limited1992-12-312015-10-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
E.E.s 400tablet400 mg/1oralArbor Pharmaceuticals, Inc.2011-05-03Not applicableUs
E.E.S.tablet, film coated400 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-16Not applicableUs
E.E.S.tablet, film coated400 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-16Not applicableUs
Erysolution.8 mL/100mLtopicalPerrigo New York Inc2008-07-07Not applicableUs
Ery-tabtablet, delayed release250 mg/1oralCarilion Materials Management2011-04-18Not applicableUs
Ery-tabtablet, delayed release500 mg/1oralArbor Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralPhysicians Total Care, Inc.1999-09-28Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralArbor Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralA S Medication Solutions Llc2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralSTAT Rx USA LLC2011-04-18Not applicableUs
Ery-tabtablet, delayed release250 mg/1oralArbor Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralKAISER FOUNDATION HOSPITALS2009-08-28Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralRebel Distributors Corp1972-07-11Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralPd Rx Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet, delayed release250 mg/1oralA S Medication Solutions Llc2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralPd Rx Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet333 mg/1oralREMEDYREPACK INC.2011-08-19Not applicableUs
Ery-tabtablet, delayed release500 mg/1oralA S Medication Solutions Llc2011-04-18Not applicableUs
Ery-tabtablet, delayed release500 mg/1oralPd Rx Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet, delayed release500 mg/1oralREMEDYREPACK INC.2011-08-24Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralSTAT Rx USA LLC2011-04-18Not applicableUs
Ery-tabtablet, delayed release500 mg/1oralPhysicians Total Care, Inc.2004-06-30Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralCarilion Materials Management2011-04-18Not applicableUs
Erygelgel20 mg/gtopicalPrestium Pharma, Inc.2014-01-27Not applicableUs
Erythrocin Lactobionateinjection, powder, lyophilized, for solution500 mg/100mLintravenousHospira, Inc.1986-10-31Not applicableUs
Erythrocin Stearatetablet, film coated500 mg/1oralbryant ranch prepack1964-06-24Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralA S Medication Solutions Llc2011-08-01Not applicableUs
Erythrocin Stearatetablet500 mg/1oralREMEDYREPACK INC.2012-08-27Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralREMEDYREPACK INC.2013-03-05Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralA S Medication Solutions Llc2011-08-01Not applicableUs
Erythrocin Stearatetablet, film coated500 mg/1oralBlenheim Pharmacal, Inc.2010-09-14Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralKAISER FOUNDATION HOSPITALS2012-01-06Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralArbor Pharmaceuticals, Inc.2011-08-01Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralPd Rx Pharmaceuticals, Inc.2011-08-01Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralBlenheim Pharmacal, Inc.2010-03-09Not applicableUs
Erythromycintablet, film coated250 mg/1oralArbor Pharmaceuticals, Inc.2011-09-06Not applicableUs
Erythromycinointment5 mg/gophthalmicAkorn, Inc.2013-03-11Not applicableUs
Erythromycinointment5 mg/gophthalmicREMEDYREPACK INC.2013-05-06Not applicableUs
Erythromycinointment5 mg/gophthalmicProficient Rx LP1994-07-29Not applicableUs
Erythromycinointment5 mg/gophthalmicAkorn, Inc.1996-07-18Not applicableUs
Erythromycinointment5 mg/gophthalmicPaddock Laboratories, LLC2014-05-08Not applicableUs
Erythromycinsolution20 mg/mLtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1997-09-30Not applicableUs
Erythromycinointment5 mg/gophthalmicFera Pharmaceuticals2010-01-18Not applicableUs
Erythromycinsolution20 mg/1topicalPhysicians Total Care, Inc.1996-03-29Not applicableUs
Erythromycinointment5 mg/gophthalmicProficient Rx LP1996-07-18Not applicableUs
Erythromycintablet, film coated250 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Erythromycintablet, film coated250 mg/1oralSTAT Rx USA LLC1972-07-11Not applicableUs
Erythromycinointment5 mg/gophthalmicLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2010-01-18Not applicableUs
Erythromycingel20 mg/gtopicalPerrigo New York Inc2008-06-12Not applicableUs
Erythromycinointment5 g/1ophthalmicDIRECT RX2014-01-01Not applicableUs
Erythromycincapsule, delayed release250 mg/1oralA S Medication Solutions Llc2012-01-10Not applicableUs
Erythromycinointment5 mg/gophthalmicPreferred Pharmaceuticals, Inc.2013-08-05Not applicableUs
Erythromycinointment5 mg/gophthalmicStat Rx USA1994-07-29Not applicableUs
Erythromycinointment5 mg/gophthalmicPhysicians Total Care, Inc.1994-09-01Not applicableUs
Erythromycinsolution20 mg/mLtopicalVersa Pharm Incorporated2010-08-01Not applicableUs
Erythromycinointment5 mg/gophthalmicCardinal Health1994-07-29Not applicableUs
Erythromycinointment5 mg/gophthalmicPreferred Pharmaceuticals, Inc.2014-07-03Not applicableUs
Erythromycinointment5 mg/gophthalmicHenry Schein Inc.2015-05-13Not applicableUs
Erythromycinointment5 mg/gophthalmicBausch & Lomb Incorporated1994-07-29Not applicableUs
Erythromycincapsule, delayed release250 mg/1oralStat Rx USA1986-12-22Not applicableUs
Erythromycincapsule, delayed release250 mg/1oralArbor Pharmaceuticals, Inc.2012-01-10Not applicableUs
Erythromycinsolution20 mg/mLtopicalPerrigo New York Inc2011-12-19Not applicableUs
Erythromycinsolution20 mg/mLtopicalMorton Grove Pharmaceuticals, Inc.1987-10-23Not applicableUs
Erythromycinointment5 mg/gophthalmicA S Medication Solutions Llc1996-07-18Not applicableUs
Erythromycinointment5 mg/gophthalmicPreferred Pharmaceuticals, Inc.2015-04-02Not applicableUs
Erythromycinointment5 mg/gophthalmicMwi2015-03-23Not applicableUs
Erythromycincapsule, delayed release250 mg/1oralKAISER FOUNDATION HOSPITALS2012-04-26Not applicableUs
Erythromycinointment5 mg/gophthalmicCardinal Health1996-07-18Not applicableUs
Erythromycinointment5 mg/gophthalmicPreferred Pharmaceuticals, Inc.1996-07-18Not applicableUs
Erythromycingel20 mg/gtopicalAidarex Pharmaceuticals LLC2008-06-12Not applicableUs
Erythromycinointment5 mg/gophthalmicDispensing Solutions, Inc.1996-07-18Not applicableUs
Erythromycinointment5 mg/gophthalmicREMEDYREPACK INC.2013-12-31Not applicableUs
Erythromycintablet, film coated500 mg/1oralArbor Pharmaceuticals, Inc.2011-09-06Not applicableUs
Erythromycinointment5 mg/gophthalmicRebel Distributors Corp1994-07-29Not applicableUs
Erythromycinointment5 mg/gophthalmicH.J. Harkins Company, Inc.1994-07-29Not applicableUs
Erythromycinointment5 mg/gophthalmicCentral Texas Community Health Centers1994-07-29Not applicableUs
Erythromycingel20 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1997-09-30Not applicableUs
Erythromycin Basetablet, film coated500 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-09-06Not applicableUs
Erythromycin Basetablet, film coated500 mg/1oralA S Medication Solutions Llc2011-09-06Not applicableUs
Erythromycin Basetablet, film coated250 mg/1oralA S Medication Solutions Llc2011-09-06Not applicableUs
Erythromycin Basetablet, film coated500 mg/1oralPd Rx Pharmaceuticals, Inc.2011-09-06Not applicableUs
Erythromycin Basetablet, film coated250 mg/1oralCarilion Materials Management2011-09-06Not applicableUs
Erythromycin Base Basetablet, film coated250 mg/1oralREMEDYREPACK INC.2013-03-14Not applicableUs
Erythromycin Base Basetablet, film coated250 mg/1oralPd Rx Pharmaceuticals, Inc.2011-09-06Not applicableUs
Erythromycin Base Basetablet, film coated500 mg/1oralREMEDYREPACK INC.2013-03-04Not applicableUs
Erythromycin Base Filmtabtablet, film coated250 mg/1oralPhysicians Total Care, Inc.1995-07-21Not applicableUs
Erythromycin Base Filmtabtablet, film coated500 mg/1oralPhysicians Total Care, Inc.1996-12-09Not applicableUs
Erythromycin Base Filmtabtablet, film coated500 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-12Not applicableUs
Erythromycin Base Filmtabtablet, film coated500 mg/1oralCardinal Health2011-09-08Not applicableUs
Erythromycin Base Filmtabtablet, film coated500 mg/1oralRebel Distributors Corp1972-07-11Not applicableUs
Erythromycin Base Filmtabtablet, film coated250 mg/1oralRebel Distributors Corp1972-07-11Not applicableUs
Erythromycin Ethylsuccinatetablet400 mg/1oralPhysicians Total Care, Inc.1996-02-27Not applicableUs
Erythromycin Ethylsuccinatetablet400 mg/1oralArbor Pharmaceuticals, Inc.2011-10-03Not applicableUs
Erythromycin Ethylsuccinatetablet400 mg/1oralA S Medication Solutions Llc2011-10-03Not applicableUs
Ilotycinointment.5 mg/gophthalmicFera Pharmaceuticals, LLC2010-10-12Not applicableUs
Ilotycinointment5 mg/gophthalmicPaddock Laboratories, LLC2014-10-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ErycHospira
IlosoneCipa
StaticinWestwood
T-statWestwood
Brand mixtures
NameLabellerIngredients
BenzamycinDermik Laboratories
ErysolGlaxosmithkline Inc
Erythromycin and Benzoyl PeroxideLyne Laboratories, Inc.
Erythromycin Ethylsuccinate and Sulfisoxazole AcetylRebel Distributors Corp
Erythromycin-benzoyl PeroxidePerrigo New York Inc
PediazoleAmdipharm Limited
Sans-acne SolutionGalderma Canada Inc
Stievamycin ForteGlaxosmithkline Inc
Stievamycin MildGlaxosmithkline Inc
Stievamycin RegularGlaxosmithkline Inc
T-stat LotWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
T-stat Pad-lotWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
Salts
Name/CASStructureProperties
Erythromycin estolate
ThumbNot applicableDBSALT001358
Erythromycin ethylsuccinate
ThumbNot applicableDBSALT001220
Erythromycin gluceptate
ThumbNot applicableDBSALT001340
Erythromycin lactobionate
ThumbNot applicableDBSALT001219
Erythromycin phosphate
ThumbNot applicableDBSALT001624
Erythromycin stearate
ThumbNot applicableDBSALT001221
Erythromycin thiocyanate
ThumbNot applicableDBSALT001625
Categories
UNII63937KV33D
CAS number114-07-8
WeightAverage: 733.9268
Monoisotopic: 733.461241235
Chemical FormulaC37H67NO13
InChI KeyInChIKey=ULGZDMOVFRHVEP-RWJQBGPGSA-N
InChI
InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
IUPAC Name
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
SMILES
CC[[email protected]]1OC(=O)[[email protected]](C)[C@@H](O[[email protected]]2C[C@@](C)(OC)[C@@H](O)[[email protected]](C)O2)[[email protected]](C)[C@@H](O[C@@H]2O[[email protected]](C)C[C@@H]([[email protected]]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[[email protected]](C)[C@@H](O)[C@]1(C)O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolides and analogues
Sub ClassNot Available
Direct ParentMacrolides and analogues
Alternative Parents
Substituents
  • Macrolide
  • Amino sugar
  • Desosamine
  • Amino saccharide
  • Oxane
  • Monosaccharide
  • Saccharide
  • Tertiary alcohol
  • Cyclic ketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Polyol
  • Lactone
  • Ketone
  • Carboxylic acid ester
  • 1,2-diol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree, pertussis (whooping cough), as adjunct to antitoxin in infections due to Corynebacterium diphtheriae, in the treatment of infections due to Corynebacterium minutissimum, intestinal amebiasis caused by Entamoeba histolytica, acute pelvic inflammatory disease caused by Neisseria gonorrhoeae, skin and soft tissue infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus, primary syphilis caused by Treponema pallidum, infections caused by Chlamydia trachomatis, nongonococcal urethritis caused by Ureaplasma urealyticum, and Legionnaires' disease caused by Legionella pneumophila.
PharmacodynamicsErythromycin is produced by a strain of Streptomyces erythraeus and belongs to the macrolide group of antibiotics. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid, but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin is excreted in breast milk. The drug crosses the placental barrier with fetal serum drug levels reaching 5 - 20% of maternal serum concentrations. Erythromycin is not removed by peritoneal dialysis or hemodialysis.
Mechanism of actionErythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the “P” or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the “A” or acceptor site to the “P” or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug.
Related Articles
AbsorptionOrally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Topical application of the ophthalmic ointment to the eye may result in absorption into the cornea and aqueous humor.
Volume of distributionNot Available
Protein bindingErythromycin is largely bound to plasma proteins, ranging from 75 - 95% binding depending on the form.
Metabolism

Hepatic. Extensively metabolized - after oral administration, less than 5% of the administered dose can be recovered in the active form in the urine. Erythromycin is partially metabolized by CYP3A4 resulting in numerous drug interactions.

SubstrateEnzymesProduct
Erythromycin
norerythromycinDetails
Route of eliminationNot Available
Half life0.8 - 3 hours
ClearanceNot Available
ToxicitySymptoms of overdose include diarrhea, nausea, stomach cramps, and vomiting.
Affected organisms
  • Enteric bacteria and other eubacteria
  • Streptococcus pyogenes
  • Haemophilus influenzae
  • Staphylococcus aureus
Pathways
PathwayCategorySMPDB ID
Erythromycin Action PathwayDrug actionSMP00250
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5114
Blood Brain Barrier-0.9889
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8098
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.5963
Renal organic cation transporterNon-inhibitor0.9222
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9225
CYP450 3A4 substrateSubstrate0.6528
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9074
CYP450 3A4 inhibitorNon-inhibitor0.5744
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9391
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9335
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2296 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9902
hERG inhibition (predictor II)Non-inhibitor0.8956
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
  • Parke davis div warner lambert co
  • Warner chilcott inc
  • Abbott laboratories pharmaceutical products div
  • Barr laboratories inc
  • Stiefel laboratories inc
  • Altana inc
  • Merz pharmaceuticals llc
  • Perrigo co
  • Syosset laboratories inc
  • Akorn inc
  • Bausch and lomb pharmaceuticals inc
  • E fougera div altana inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Dista products co div eli lilly and co
  • Dow pharmaceutical sciences inc
  • Paddock laboratories inc
  • Taro pharmaceuticals north america inc
  • Bioglan pharma inc
  • Alpharma us pharmaceuticals division
  • Eli lilly and co
  • Perrigo new york inc
  • Wockhardt eu operations (swiss) ag
  • Hi tech pharmacal co inc
  • Westwood squibb pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Orthoneutrogena
  • Versapharm inc
  • Ah robins co
  • Solvay pharmaceuticals
  • Watson laboratories inc
  • Life laboratories inc
  • Lilly research laboratories div eli lilly and co
  • Ross laboratories div abbott laboratories inc
  • Pharmacia and upjohn co
  • Naska pharmacal co inc div rugby darby group cosmetics
  • Wyeth ayerst laboratories
  • Abbott laboratories chemical and agricultural products div
  • Mylan pharmaceuticals inc
  • Elkins sinn div ah robins co inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Teva parenteral medicines inc
  • Bristol laboratories inc div bristol myers co
  • Warner chilcott div warner lambert co
  • Lederle laboratories div american cyanamid co
  • Purepac pharmaceutical co
  • Bristol myers squibb co
  • Pfizer laboratories div pfizer inc
Packagers
Dosage forms
FormRouteStrength
Tablet (enteric-coated)oral250 mg
Kit
Ointmentophthalmic5 mg
Granule, for suspensionoral200 mg/5mL
Tabletoral400 mg/1
Tablet, film coatedoral400 mg/1
Tabletoral600 mg
Powder for suspensionoral40 mg
Tabletoral200 mg
Powder for suspensionoral400 mg
Solutiontopical.8 mL/100mL
Suspensionoral200 mg/5mL
Suspensionoral400 mg/5mL
Tablet, delayed releaseoral250 mg/1
Tablet, delayed releaseoral333 mg/1
Tablet, delayed releaseoral500 mg/1
Tabletoral500 mg
Capsule (enteric-coated)oral250 mg
Capsule (enteric-coated)oral333 mg
Tabletoral250 mg
Powder for solutionintravenous1 g
Powder for solutionintravenous500 mg
Injection, powder, lyophilized, for solutionintravenous500 mg/10mL
Injection, powder, lyophilized, for solutionintravenous500 mg/100mL
Liquidoral50 mg
Liquidoral25 mg
Tabletoral500 mg/1
Tablet, film coatedoral250 mg/1
Tablet, film coatedoral500 mg/1
Capsule, delayed releaseoral250 mg/1
Capsule, delayed release pelletsoral250 mg/1
Geltopical20 mg/g
Ointmentophthalmic5 g/1
Ointmentophthalmic5 mg/g
Solutiontopical20 mg/1
Solutiontopical20 mg/mL
Geltopical
Kittopical
Granule, for suspensionoral
Capsuleoral250 mg
Ointmentophthalmic.5 mg/g
Ointmentophthalmic.5 %
Suspensionoral125 mg
Suspensionoral250 mg
Powderoral400 mg
Powder for solutionoral100 mg
Powder for solutionoral200 mg
Tabletoral333 mg
Tabletoral333 mg/1
Powder for suspensionoral
Solutiontopical
Lotiontopical
Lotion; padtopical
Prices
Unit descriptionCostUnit
Benzamycin 5-3% Gel 46.6 gm Jar236.63USD jar
BenzamycinPak 60 5-3% Packets (2 Box Contains 60 Packets)142.45USD packet
Erythromycin 2% Gel 60 gm Tube46.8USD tube
Erycette 60 2% Pad Box30.99USD box
Erythromycin 2% Gel 30 gm Tube26.2USD tube
Erythromycin 2% Solution 60ml Bottle26.13USD bottle
Eryderm 2% Solution 60ml Bottle25.99USD bottle
Erythromycin 5 mg/gm Ointment Limited Supply Available.13.99USD tube
Benzamycin gel4.95USD g
Akne-mycin 2% ointment3.96USD g
PCE 500 mg Enteric Coated Tabs3.28USD tab
Pce 500 mg dispertab3.03USD tablet
PCE 333 mg Enteric Coated Tabs2.48USD tab
Erythromycin e.s. powder2.39USD g
Benzamycinpak gel2.37USD gel
Pce 333 mg dispertab2.3USD tablet
Romycin eye ointment1.98USD g
Erythromycin eye ointment1.44USD g
Pms-Erythromycin 0.5 % Ointment1.3USD g
Emgel 2% topical gel1.07USD g
Ery-Tab 500 mg Enteric Coated Tabs0.93USD tab
Ery-tab 500 mg tablet ec0.77USD tablet
Ery-Tab 333 mg Enteric Coated Tabs0.72USD tab
Erythro-rx powder0.72USD g
Erythromycin ec 500 mg tablet0.66USD tablet
Erythromycin Base 500 mg tablet0.61USD tablet
Eryc 333 mg Capsule (Enteric-Coated Pellet)0.6USD capsule
Apo-Erythro-S 500 mg Tablet0.57USD tablet
E-mycin 333 mg tablet ec0.54USD tablet
Eryc 250 mg Capsule (Enteric-Coated Pellet)0.54USD capsule
Erythromycin powder0.54USD g
Erythromycin 2% gel0.5USD g
Erythromycin Base 250 mg Enteric Coated Capsule0.5USD capsule
Erythromycin Base 250 mg tablet0.5USD tablet
Ery-tab ec 500 mg tablet0.46USD tablet
Apo-Erythro E-C 333 mg Capsule (Enteric-Coated Pellet)0.45USD capsule
Ery-Tab 250 mg Enteric Coated Tabs0.45USD tab
Erythromycin st 500 mg tablet0.44USD tablet
Apo-Erythro E-C 250 mg Capsule (Enteric-Coated Pellet)0.41USD capsule
Ery-tab 333 mg tablet ec0.4USD tablet
Apo-Erythro-Es 600 mg Tablet0.35USD tablet
Erythromycin 500 mg filmtab0.3USD tablet
Erythrocin 500 mg filmtab0.29USD tablet
Ery-tab 250 mg tablet ec0.27USD tablet
E.e.s. 400 filmtab0.25USD tablet
Erythromycin 250 mg filmtab0.25USD tablet
Erythromycin es 400 mg tablet0.25USD tablet
Apo-Erythro-S 250 mg Tablet0.22USD tablet
Apo-Erythro Base 250 mg Tablet0.19USD tablet
Erythrocin 250 mg filmtab0.16USD tablet
Novo-Rythro Ees 80 mg/ml Suspension0.15USD ml
Novo-Rythro Estolate 50 mg/ml Suspension0.13USD ml
Novo-Rythro Ees 40 mg/ml Suspension0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point191 °CPhysProp
water solubility2000mg/L at 28°CEuropean Pharmacopeia
logP3.06MCFARLAND,JW ET AL. (1997)
Caco2 permeability-5.43ADME Research, USCD
pKa8.88 (at 25 °C)MCFARLAND,JW ET AL. (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.459 mg/mLALOGPS
logP2.37ALOGPS
logP2.6ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.44ChemAxon
pKa (Strongest Basic)8.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area193.91 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity186.04 m3·mol-1ChemAxon
Polarizability78.21 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Takehiro Amano, Masami Goi, Kazuto Sekiuchi, Tomomichi Yoshida, Masahiro Hasegawa, “Process for preparing erythromycin A oxime or a salt thereof.” U.S. Patent US5274085, issued October, 1966.

US5274085
General References
  1. Kanazawa S, Ohkubo T, Sugawara K: The effects of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):799-803. [PubMed:11294369 ]
  2. Ogwal S, Xide TU: Bioavailability and stability of erythromycin delayed release tablets. Afr Health Sci. 2001 Dec;1(2):90-6. [PubMed:12789122 ]
  3. Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K: Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol. 2007 Jul;47(7):871-6. [PubMed:17585116 ]
External Links
ATC CodesD10AF02D10AF52J01FA01S01AA17
AHFS Codes
  • 08:12.12.04
  • 34:00.00
  • 52:04.04
PDB EntriesNot Available
FDA labelDownload (149 KB)
MSDSDownload (73 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Erythromycin.
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Erythromycin.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Erythromycin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Erythromycin.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Erythromycin.
AlogliptinAlogliptin may increase the hypoglycemic activities of Erythromycin.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Erythromycin.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Erythromycin.
AmrinoneThe metabolism of Amrinone can be decreased when combined with Erythromycin.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Erythromycin.
AprepitantThe serum concentration of Erythromycin can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Erythromycin.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Erythromycin.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Erythromycin.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Erythromycin.
BepridilThe metabolism of Bepridil can be decreased when combined with Erythromycin.
BexaroteneThe serum concentration of Erythromycin can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Erythromycin can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Erythromycin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Erythromycin.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Erythromycin.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Erythromycin.
BuspironeThe metabolism of Buspirone can be decreased when combined with Erythromycin.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Erythromycin.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Erythromycin.
ChlorpropamideErythromycin may increase the hypoglycemic activities of Chlorpropamide.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Erythromycin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Erythromycin.
CitalopramErythromycin may increase the QTc-prolonging activities of Citalopram.
ClindamycinThe therapeutic efficacy of Clindamycin can be decreased when used in combination with Erythromycin.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Erythromycin.
ClozapineThe metabolism of Clozapine can be decreased when combined with Erythromycin.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Erythromycin.
ConivaptanThe serum concentration of Erythromycin can be increased when it is combined with Conivaptan.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Erythromycin.
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Erythromycin.
DabrafenibThe serum concentration of Erythromycin can be decreased when it is combined with Dabrafenib.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Erythromycin.
DasatinibThe serum concentration of Erythromycin can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Erythromycin can be decreased when it is combined with Deferasirox.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Erythromycin.
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Erythromycin.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Erythromycin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Erythromycin.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Erythromycin.
DisopyramideErythromycin may increase the QTc-prolonging activities of Disopyramide.
DofetilideErythromycin may increase the QTc-prolonging activities of Dofetilide.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Erythromycin.
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Erythromycin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Erythromycin.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Erythromycin.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Erythromycin.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Erythromycin.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Erythromycin.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Erythromycin.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Erythromycin.
FelodipineThe metabolism of Felodipine can be decreased when combined with Erythromycin.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Erythromycin.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Erythromycin.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Erythromycin.
FloxuridineThe metabolism of Erythromycin can be decreased when combined with Floxuridine.
FluconazoleFluconazole may increase the QTc-prolonging activities of Erythromycin.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Erythromycin.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Erythromycin.
FosaprepitantThe serum concentration of Erythromycin can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Erythromycin can be increased when it is combined with Fusidic Acid.
GabapentinThe metabolism of Gabapentin can be decreased when combined with Erythromycin.
GliclazideGliclazide may increase the hypoglycemic activities of Erythromycin.
GlimepirideGlimepiride may increase the hypoglycemic activities of Erythromycin.
GliquidoneGliquidone may increase the hypoglycemic activities of Erythromycin.
GlyburideGlyburide may increase the hypoglycemic activities of Erythromycin.
GoserelinGoserelin may increase the QTc-prolonging activities of Erythromycin.
HexamethylenetetramineThe risk or severity of adverse effects can be increased when Hexamethylenetetramine is combined with Erythromycin.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Erythromycin.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Erythromycin.
IdelalisibThe serum concentration of Erythromycin can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Erythromycin resulting in a loss in efficacy.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Erythromycin.
Insulin AspartInsulin Aspart may increase the hypoglycemic activities of Erythromycin.
Insulin DetemirInsulin Detemir may increase the hypoglycemic activities of Erythromycin.
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Erythromycin.
Insulin GlulisineInsulin Glulisine may increase the hypoglycemic activities of Erythromycin.
Insulin HumanInsulin Regular may increase the hypoglycemic activities of Erythromycin.
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Erythromycin.
IsradipineThe metabolism of Isradipine can be decreased when combined with Erythromycin.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Erythromycin.
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Erythromycin.
LamotrigineThe metabolism of Lamotrigine can be decreased when combined with Erythromycin.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Erythromycin.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Erythromycin.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Erythromycin.
LinagliptinLinagliptin may increase the hypoglycemic activities of Erythromycin.
LincomycinThe therapeutic efficacy of Erythromycin can be decreased when used in combination with Lincomycin.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Erythromycin.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Erythromycin.
LuliconazoleThe serum concentration of Erythromycin can be increased when it is combined with Luliconazole.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Erythromycin.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be decreased when combined with Erythromycin.
MequitazineErythromycin may increase the arrhythmogenic activities of Mequitazine.
MetforminMetformin may increase the hypoglycemic activities of Erythromycin.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Erythromycin.
MifepristoneMifepristone may increase the QTc-prolonging activities of Erythromycin.
MitotaneThe serum concentration of Erythromycin can be decreased when it is combined with Mitotane.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Erythromycin.
NelfinavirThe metabolism of Erythromycin can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Erythromycin can be increased when it is combined with Netupitant.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Erythromycin.
NimodipineThe metabolism of Nimodipine can be decreased when combined with Erythromycin.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Erythromycin.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Erythromycin.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Erythromycin.
OctreotideOctreotide may increase the QTc-prolonging activities of Erythromycin.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Erythromycin.
OxandroloneOxandrolone may increase the hypoglycemic activities of Erythromycin.
OxycodoneThe risk or severity of adverse effects can be increased when Erythromycin is combined with Oxycodone.
PalbociclibThe serum concentration of Erythromycin can be increased when it is combined with Palbociclib.
ParoxetineParoxetine may increase the hypoglycemic activities of Erythromycin.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Erythromycin.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Erythromycin.
PhenelzinePhenelzine may increase the hypoglycemic activities of Erythromycin.
PhenytoinThe metabolism of Erythromycin can be increased when combined with Phenytoin.
Picosulfuric acidThe therapeutic efficacy of Sodium picosulfate can be decreased when used in combination with Erythromycin.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Erythromycin.
PimozideErythromycin may increase the QTc-prolonging activities of Pimozide.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Erythromycin.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Erythromycin.
PrenylamineThe metabolism of Prenylamine can be decreased when combined with Erythromycin.
QuinidineErythromycin may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Erythromycin.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Erythromycin.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Erythromycin.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Erythromycin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Erythromycin.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Erythromycin.
RisedronateThe metabolism of Risedronate can be decreased when combined with Erythromycin.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Erythromycin.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Erythromycin.
SaquinavirThe serum concentration of Erythromycin can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Erythromycin.
SecobarbitalThe metabolism of Erythromycin can be increased when combined with Secobarbital.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Erythromycin.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Erythromycin.
SiltuximabThe serum concentration of Erythromycin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Erythromycin.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Erythromycin.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Erythromycin.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Erythromycin.
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Erythromycin.
St. John's WortThe serum concentration of Erythromycin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Erythromycin can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Erythromycin can be decreased when combined with Sulfisoxazole.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Erythromycin.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Erythromycin.
TelaprevirThe serum concentration of Erythromycin can be increased when it is combined with Telaprevir.
TemsirolimusThe risk or severity of adverse effects can be increased when Erythromycin is combined with Temsirolimus.
TerfenadineErythromycin may increase the QTc-prolonging activities of Terfenadine.
TesmilifeneThe serum concentration of Erythromycin can be decreased when it is combined with Tesmilifene.
TestosteroneTestosterone may increase the hypoglycemic activities of Erythromycin.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Erythromycin.
TocilizumabThe serum concentration of Erythromycin can be decreased when it is combined with Tocilizumab.
TolbutamideTolbutamide may increase the hypoglycemic activities of Erythromycin.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Erythromycin.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Erythromycin.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Erythromycin.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Erythromycin.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Erythromycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Erythromycin.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Erythromycin.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Erythromycin.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Erythromycin.
VildagliptinVildagliptin may increase the hypoglycemic activities of Erythromycin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Erythromycin.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Erythromycin.
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Erythromycin.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Erythromycin.
Food Interactions
  • Avoid alcohol.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water Avoid taking with grapefruit juice.

Targets

1. 23S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
yes
Actions
inhibitor
References
  1. Moazed D, Noller HF: Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochimie. 1987 Aug;69(8):879-84. [PubMed:3122849 ]
  2. Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. [PubMed:11677599 ]
  3. Garza-Ramos G, Xiong L, Zhong P, Mankin A: Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. J Bacteriol. 2001 Dec;183(23):6898-907. [PubMed:11698379 ]
Kind
Protein
Organism
Escherichia coli O157:H7
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of ribosome
Specific Function:
This protein binds specifically to 23S rRNA; its binding is stimulated by other ribosomal proteins, e.g. L4, L17, and L20. It is important during the early stages of 50S assembly. It makes multiple contacts with different domains of the 23S rRNA in the assembled 50S subunit and ribosome (By similarity).The globular domain of the protein is located near the polypeptide exit tunnel on the outside...
Gene Name:
rplV
Uniprot ID:
P61177
Molecular Weight:
12226.165 Da
References
  1. Halling SM, Jensen AE: Intrinsic and selected resistance to antibiotics binding the ribosome: analyses of Brucella 23S rrn, L4, L22, EF-Tu1, EF-Tu2, efflux and phylogenetic implications. BMC Microbiol. 2006 Oct 2;6:84. [PubMed:17014718 ]
  2. Tu D, Blaha G, Moore PB, Steitz TA: Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell. 2005 Apr 22;121(2):257-70. [PubMed:15851032 ]
  3. Rolain JM, Raoult D: Prediction of resistance to erythromycin in the genus Rickettsia by mutations in L22 ribosomal protein. J Antimicrob Chemother. 2005 Aug;56(2):396-8. Epub 2005 Jul 4. [PubMed:15996971 ]
  4. Cagliero C, Mouline C, Cloeckaert A, Payot S: Synergy between efflux pump CmeABC and modifications in ribosomal proteins L4 and L22 in conferring macrolide resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother. 2006 Nov;50(11):3893-6. Epub 2006 Aug 28. [PubMed:16940070 ]
  5. Schlunzen F, Harms JM, Franceschi F, Hansen HA, Bartels H, Zarivach R, Yonath A: Structural basis for the antibiotic activity of ketolides and azalides. Structure. 2003 Mar;11(3):329-38. [PubMed:12623020 ]
  6. Davydova N, Streltsov V, Wilce M, Liljas A, Garber M: L22 ribosomal protein and effect of its mutation on ribosome resistance to erythromycin. J Mol Biol. 2002 Sep 20;322(3):635-44. [PubMed:12225755 ]
Kind
Protein
Organism
Escherichia coli O157:H7
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of ribosome
Specific Function:
One of the primary rRNA binding proteins, this protein initially binds near the 5'-end of the 23S rRNA. It is important during the early stages of 50S assembly. It makes multiple contacts with different domains of the 23S rRNA in the assembled 50S subunit and ribosome.Protein L4 is a both a transcriptional repressor and a translational repressor protein. It regulates transcription of the S10 op...
Gene Name:
rplD
Uniprot ID:
P60725
Molecular Weight:
22086.36 Da
References
  1. Halling SM, Jensen AE: Intrinsic and selected resistance to antibiotics binding the ribosome: analyses of Brucella 23S rrn, L4, L22, EF-Tu1, EF-Tu2, efflux and phylogenetic implications. BMC Microbiol. 2006 Oct 2;6:84. [PubMed:17014718 ]
  2. Tu D, Blaha G, Moore PB, Steitz TA: Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell. 2005 Apr 22;121(2):257-70. [PubMed:15851032 ]
  3. O'Connor M, Gregory ST, Dahlberg AE: Multiple defects in translation associated with altered ribosomal protein L4. Nucleic Acids Res. 2004 Oct 27;32(19):5750-6. Print 2004. [PubMed:15509870 ]
  4. Schlunzen F, Harms JM, Franceschi F, Hansen HA, Bartels H, Zarivach R, Yonath A: Structural basis for the antibiotic activity of ketolides and azalides. Structure. 2003 Mar;11(3):329-38. [PubMed:12623020 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Growth hormone-releasing hormone receptor activity
Specific Function:
Receptor for motilin.
Gene Name:
MLNR
Uniprot ID:
O43193
Molecular Weight:
45343.725 Da
References
  1. Li JJ, Chao HG, Wang H, Tino JA, Lawrence RM, Ewing WR, Ma Z, Yan M, Slusarchyk D, Seethala R, Sun H, Li D, Burford NT, Stoffel RH, Salyan ME, Li CY, Witkus M, Zhao N, Rich A, Gordon DA: Discovery of a potent and novel motilin agonist. J Med Chem. 2004 Mar 25;47(7):1704-8. [PubMed:15027861 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Du LP, Tsai KC, Li MY, You QD, Xia L: The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4771-7. [PubMed:15324906 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sterol 14-demethylase activity
Specific Function:
Catalyzes C14-demethylation of lanosterol; it transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
Gene Name:
CYP51A1
Uniprot ID:
Q16850
Molecular Weight:
56805.26 Da
References
  1. Ekins S, Mankowski DC, Hoover DJ, Lawton MP, Treadway JL, Harwood HJ Jr: Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007 Mar;35(3):493-500. Epub 2006 Dec 28. [PubMed:17194716 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Baneres-Roquet F, Gualtieri M, Villain-Guillot P, Pugniere M, Leonetti JP: Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. Antimicrob Agents Chemother. 2009 Apr;53(4):1528-31. doi: 10.1128/AAC.00971-08. Epub 2009 Jan 21. [PubMed:19164148 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Monovalent cation:proton antiporter activity
Specific Function:
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, ganciclovir and also the zwitterionic cephalosporin, cephalexin and cephradin. Seems to also play a role in the uptake of oxaliplatin (a new platinum anticancer agent). Able to transport...
Gene Name:
SLC47A1
Uniprot ID:
Q96FL8
Molecular Weight:
61921.585 Da
References
  1. Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM: Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 2013 Feb 14;56(3):781-95. doi: 10.1021/jm301302s. Epub 2013 Jan 22. [PubMed:23241029 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Lexicomp

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764 ]
  2. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  3. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  4. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  5. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T: Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol. 1998 Oct 9;358(3):289-94. [PubMed:9822896 ]
  6. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372 ]
  7. Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K, Shimizu A, Miyoshi M, Takagi K, Takagi K, Hasegawa T: Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol. 2004 Jan 26;484(2-3):333-9. [PubMed:14744620 ]
  8. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
  9. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690 ]
  10. Sun H, Huang Y, Frassetto L, Benet LZ: Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004 Nov;32(11):1239-46. Epub 2004 Jul 30. [PubMed:15286055 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Terashi K, Oka M, Soda H, Fukuda M, Kawabata S, Nakatomi K, Shiozawa K, Nakamura T, Tsukamoto K, Noguchi Y, Suenaga M, Tei C, Kohno S: Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells. Antimicrob Agents Chemother. 2000 Jun;44(6):1697-700. [PubMed:10817732 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T: Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22. Epub 2005 Feb 11. [PubMed:15708966 ]
  2. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T: Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. [PubMed:12065749 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on February 04, 2016 11:50